Publication of a Transparency Notification Received from Armistice Capital, LLC
September 12 2023 - 11:45AM
Publication of a Transparency Notification Received from Armistice
Capital, LLC
Publication of a
Transparency
Notification
Received from Armistice
Capital, LLC
Liege,
Belgium,
12 September
2023
–
5:45pm
CEST – Mithra
(Euronext Brussels: MITRA), a company dedicated to Women’s Health,
today announces, in accordance with Article 14 of the Belgian Law
of 2 May 2007 regarding the publication of major shareholdings in
issuers whose securities are admitted to trading on a regulated
market (the “Transparency Law”), that it received a notification of
transparency from Armistice Capital, LLC, with registered offices
at 510 Madison Avenue, 7th Floor, NY 10022, New York, USA, on 31
August 2023.
Armistice Capital, LLC notified Mithra that it
has actively crossed above the legal 10% threshold on 28 August
2023 as a result of the completion of the Private Placement
completed on the same date1. Armistice Capital, LLC now holds
14.58% (10,000,000 shares) of the 68,587,058 shares currently
outstanding.
The detailed transparency notifications are
available on the Investors section of Mithra
(mithra.com/en/investors/). An updated overview of the Mithra’s
shareholders structure will be included in the corporate governance
charter of Mithra, which will be made available on its website.
For more information, please
contact:
Mithra Pharmaceuticals
SADavid Horn SolomonChief Executive
Officerinvestorrelations@mithra.com |
Investor &
media relationsChris MaggosCohesion
Bureauchris.maggos@cohesionbureau.com+41 79 367 6254 |
About
Mithra
Mithra Pharmaceuticals SA (Euronext: MITRA) is a
Belgian biopharmaceutical company dedicated to transforming Women’s
Health by offering new choices through innovation, with a
particular focus on contraception and menopause. Mithra’s goal is
to develop products offering better efficacy, safety and
convenience, meeting women’s needs throughout their life span.
Mithra explores the potential of the unique native estrogen
estetrol in a wide range of applications in women health and
beyond. After having successfully launched the first estetrol-based
product in 2021, the contraceptive pill Estelle®, Mithra is now
focusing on its second product Donesta®, the next-generation
hormone therapy. Mithra also offers partners a complete spectrum of
solutions from early drug development, clinical batches and
commercial manufacturing of complex polymeric products (vaginal
ring, implants) and complex liquid injectables and biologicals
(vials, pre-filled syringes or cartridges) at its technological
platform Mithra CDMO. Active in more than 100 countries around the
world, is headquartered in Liège, Belgium. www.mithra.com
Important information
The contents of this announcement include
statements that are, or may be deemed to be, "forward-looking
statements". These forward-looking statements can be identified by
the use of forward-looking terminology, including the words
"believes", "estimates," "anticipates", "expects", "intends",
"may", "will", "plans", "continue", "ongoing", "potential",
"predict", "project", "target", "seek" or "should", and include
statements the Company makes concerning the intended results of its
strategy. By their nature, forward-looking statements involve risks
and uncertainties and readers are cautioned that any such
forward-looking statements are not guarantees of future
performance. The Company's actual results may differ materially
from those predicted by the forward-looking statements. The Company
undertakes no obligation to publicly update or revise
forward-looking statements, except as may be required by law.
Subscribe to our mailing list on investors.mithra.com to receive
our press releases by email or follow us on our social media
:Linkedin • Twitter • Facebook |
1
https://www.mithra.com/en/mithra-completes-eur-20-million-private-placement-in-equity/
- 2023-09-12_Mithra-Armistice- ENG finalx
- 2023-09-12_Mithra-Armistice_FR final
Mithra Pharmaceuticals (TG:1TM)
Historical Stock Chart
From Nov 2024 to Dec 2024
Mithra Pharmaceuticals (TG:1TM)
Historical Stock Chart
From Dec 2023 to Dec 2024